• 1
    Cone RD, Mountjoy KG, Robbins LS, Nadeau JH, Johnson KR, Roselli-Rehfuss L, et al. Cloning and functional characterization of a family of receptors for the melanotropin peptides. Ann N Y Acad. Sci U S A 1993; 680: 34263.
  • 2
    Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J, et al. Characterization of receptors for alpha-melanocyte stimulating hormone on human melanoma cells. Cancer Res 1989; 49: 63528.
  • 3
    Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest 1990; 85: 182532.
  • 4
    Vaidyanathan G, Zalutsky MR. Fluorine-18–labeled [Nle4,D-Phe7]-α-MSH, an α-melanocyte stimulating hormone analog. Nucl Med Biol 1997;24: 1718.
  • 5
    Wraight EP, Bard DR, Maughan CG, Knight CG, Page-Thomas DP. The use of a chelating derivative of alpha-melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 1992; 65: 1128.
  • 6
    Bagutti C, Stolz B, Albert R, Bruns C, Pless J, Eberle AN. 111In-DPTA–labeled analogs of alpha-melanocyte–stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo. Int J Cancer 1994; 58: 74955.
  • 7
    Chen JQ, Giblin MF, Wang N, Jurisson SS, Quinn TP. In vivo evaluation of 99mTc/188Re labeled alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol 1999; 26: 68793.
  • 8
    Chen JQ, Zheng C, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mTc-labeled cyclic alpha-melanocyte stimulating hormone peptide analog. Cancer Res 2000; 60: 564958.
  • 9
    Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized though rhenium and technetium metal coordination. Proc Natl Acad Sci U S A 1998; 95: 128148.
  • 10
    Chen JQ, Wang N, Jurisson SS, Quinn TP. Biodistribution properties of linear and cyclic 99mTc labeled alpha-melanotropin peptides. Technetium, rhenium and other metals in chemistry and nuclear medicine 5, Servizi Grafici Editoriali, Padova, Italy 1999; 45763.
  • 11
    Kukis DL, DeNardo SJ, DeNardo GL, O–Donnell RT, Meares CF. Optimized conditions for chelation of Yttrium-90-DOTA immunoconjugates. J Nucl Med 1998; 39: 210510.
  • 12
    Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of Bismuth-labeled antibody. Cancer Res 1990; 50: 42216.